KPV (10mg)
Potent Anti-inflammatory
750.000 ₫
Delivery method:
Single vial
750.000 ₫
KPV pen
975.000 ₫
KPV is an α-MSH-derived tripeptide (Lys-Pro-Val) with documented anti-inflammatory and antimicrobial properties. It suppresses NF-κB signalling and pro-inflammatory cytokines (IL-6, TNF-α), calms mast-cell activation, and shows broad activity against bacteria, fungi and biofilms in published research. Researched outcomes include relief of IBD-type gut inflammation, reduced skin flares (eczema, rosacea, mast-cell skin disease), and joint-inflammation modulation. One of the most-cited anti-inflammatory peptides in translational immunology work. Often stacked with BPC-157 for gut-recovery protocols, with the Klow blend for whole-body inflammation, or with BPC-157 and TB-500 in immune protocols. Typically dosed 250–500mcg daily SubQ for 4–8 weeks. Available as 10mg or 20mg, either as a vial or a pre-loaded pen cartridge.
Dosage
Start 0.25mg once daily; after 1 week double to 0.5mg once daily
Duration of effect
Daily dosing; gut benefits build over weeks (plasma half-life: ~2-3 hours)
See full half-life table →Key Features
- Potent anti-inflammatory
- Gut health support
- Antimicrobial action
- Immune modulation
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous or intramuscular injection. May be split into multiple smaller doses throughout the day. Consult a specialist for personalized protocols.
Research Highlights
- Supports natural growth hormone production
- Improved sleep quality and recovery
- Enhanced skin health and elasticity
- Research shows improvement in cellular aging markers
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Inflammatory Bowel Diseases - ResearchGate
Clinical Research
KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, reducing inflammatory infiltrates and MPO activity significantly.
Read full studyAdditional Research
Source: Adams et al., Frontiers in Immunology (2023)
Frontiers Immunology review of the melanocortin-1 receptor pathway in inflammatory bowel disease — the broader α-MSH/KPV mechanism — including human pharmacokinetic and tolerability data on related oral MC1R agonists.
Read full study